| Backgroud:In recent years, with the development of the immune research, tumor immune therapy has become the hotspot in tumor biological therapy. Although the T cells,the T cell receptor (TCR) located in T cells surface which can recognize and bind to the antigen and participate in specific immune response, and the Vβsubfamily of TCR have being extensively studied, the characteristics, regularity and mechanism of Vβsubfamily expression of cancer patients is unclear. Moreover, such research is rarely and the expression features of Vβsubfamily and the function of T cell are not entirely clear in patients with lung cancer.Objective:In this experiment, the cytotoxic function, immune memory, and the expression of TCR Vβ24 subfamilies of peripheral T cells and that of hydrothorax tumor infiltrating lymphocytes(TILs)in patients with lung cancer was investigated. The same experiments wereIalso performed for T cells of healthy individuals, and the differences were analyzed, which would provide theoretical basis for further study on the connection among these characteristics and for deeper understanding of the basic immune in patients with lung cancer.Methods:1 T cells were isolated from either lung cancer patients or healthy individuals, and the expression of Vβsubfamily was detected with human TCR Vβkit following the manufacturer's instructions. The expression profiles and characteristics of Vβ24 subfamilies were investigated by statistical analysis.2 T cells were isolated from lung cancer patients and healthy individuals and cytotoxic effect of these T lymphocytes against the lung cancer cell line were measured by MTT assay after being stimulated with IL-2, OKT3 and cultivated for 20 days in vitro.3 In an attempt to analyze the characteristic of memory T cells between healthy individuals and lung cancer patients, the expression of CD45RO and CD28 were detected by flow cytometric method (FCM).4 To analyze the basic immune status of patients with lung cancer, the CD4+, CD8+ cells and CD4+ / CD8+ ratio were also detected by flow cytometric method (FCM)Results1 The expression of TCR Vβsubfamily Vβ3(9/49),Vβ9(10/49),Vβ13.2(6/49)was upregulated in peripheral T cells of 49 patients with lung cancer. The expression of TCR Vβsubfamily Vβ3(7/31),Vβ9(5/31),Vβ21.3(3/31)was upregulated in pleural effusion TIL of 31 patients with lung cancer. While a high percentage of Vβ5.2, Vβ5.3, Vβ7.2, Vβ13.1, Vβ14, or Vβ23 was found in different patients. Similar overexpression of Vβ3 and Vβ9 were found in peripheral T cells and hydrothorax TIL of lung cancer patients, and the Vβsubfamily expression of hydrothorax TIL was less than that of peripheral T cells in lung cancer patients.2 The cytotoxic effect of peripheral T cells (46/75) and hydrothorax TIL (53/75) in lung cancer patients were higher than that of peripheral blood T cells in healthy individuals (p < 0.05). Furthermore, cytotoxic effect of hydrothorax TIL was higher than that of peripheral blood T cells in lung cancer patients.3 Memory T cells in peripheral blood of lung cancer patients(29/35)are significantly more than those of healthy individuals(4/35)(p﹤0.05)and such memory T cells were mainly terminal effectors memory T cells ( 17/35 ) . Memory T cells in hydrothorax TIL were almost terminal effectors memory T cells, while those in peripheral blood T cells of healthy individuals were mainly primary T cells(31/35).4 The percentage of CD4+ and CD8+ and the CD4+ / CD8+ ratio in lung cancer patients were not in the scope of normal value. The expression of CD4+ and CD8+ appeared irregular and CD4+ / CD8+ ratio was inverted. Conclusion:Research on peripheral T cells and pleural effusion TILs in patients with lung cancer indicated that the TCR Vβ24 subfamilies were selectively expressed. The cytotoxic effect of peripheral blood T cells in lung cancer patients was higher than that in healthy individuals. T cells of lung cancer patients expressed mainly memory T lymphocytes. CD4+, CD8+ T cells phenotype and CD4 / CD8 ratio showed irregular and not in the normal range, which indicated disorder of basic immune in patients with lung cancer.
|
PDF Full Text Request